Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features.

[1]  C. Bredeson,et al.  Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy , 2010, Leukemia & lymphoma.

[2]  Randy D Gascoyne,et al.  The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. , 2010, Blood.

[3]  A. Rosenwald,et al.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies. , 2009, Blood.

[4]  Michael L. Wang,et al.  Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo , 2009, American journal of hematology.

[5]  C. Münz.  Non‐cytotoxic protection by human NK cells in mucosal secondary lymphoid tissues , 2008, European journal of immunology.

[6]  George Muller,et al.  Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells , 2008, Clinical Cancer Research.

[7]  Deborah A. Bowen,et al.  Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia , 2008, British journal of haematology.

[8]  Bruno Cazin,et al.  Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16 , 2008, British journal of haematology.

[9]  M. Czuczman,et al.  Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.

[10]  K. Oshimi.  Progress in understanding and managing natural killer‐cell malignancies , 2007, British journal of haematology.

[11]  M. Karjalainen‐Lindsberg,et al.  A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone , 2007, Clinical Cancer Research.

[12]  T. Hibi,et al.  Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. , 2007, Gastroenterology.

[13]  G. Salles,et al.  Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Nilsson‐Ehle,et al.  The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma , 2007, British journal of haematology.

[15]  Philip M Kluin,et al.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[17]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[18]  A. Difrancesco,et al.  Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[19]  F. Caligaris‐cappio.  Role of the microenvironment in chronic lymphocytic leukaemia , 2003, British journal of haematology.

[20]  R. Solana,et al.  Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells , 2001, Mechanisms of Ageing and Development.

[21]  P. Vandenberghe,et al.  CD57+/CD28− T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis , 1998, Leukemia.

[22]  S. Aizawa,et al.  Cytotoxic lymphocytes in the peripheral blood of patients with B cell lymphomas. , 1995, Leukemia.

[23]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[24]  R. Pabst,et al.  Distribution of lymphocyte subsets and natural killer cells in the human body , 1992, The clinical investigator.

[25]  L. Lanier,et al.  Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.

[26]  L. Lanier,et al.  A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562 , 1985, The Journal of experimental medicine.

[27]  N. Harris,et al.  Distribution of T-cell subsets in follicular and diffuse lymphomas of B-cell type. , 1983, The American journal of pathology.

[28]  G F Babcock,et al.  Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. , 1983, Journal of immunology.

[29]  M. Lipinski,et al.  Low natural killer cell activity in patients with malignant lymphoma , 1982, Cancer.

[30]  G. Trinchieri,et al.  Human natural killer cells. , 1979, Transplantation proceedings.

[31]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[32]  T. Grogan,et al.  Cytolytic (TIA-1+) tumor infiltrating lymphocytes in B cell non-Hodgkin's lymphomas. SWOG Central Repository Members. , 1993, Leukemia & lymphoma.

[33]  T. Witte,et al.  Heterogeneity of human natural killer cells in the spleen. , 1990, Immunology.

[34]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.